EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark VYDURA was filed as Word mark on 01/28/2021 at the European Union Intellectual Property Office.
It was registered as a trademark on 06/12/2021.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018384392 |
| Application date | January 28, 2021 |
| Publication date | March 5, 2021 |
| Entry date | June 12, 2021 |
| Expiration date | January 28, 2031 |
Trademark owner
Operations Support Group
Ringaskiddy,
IE
Ringaskiddy,
IE
Trademark representatives
C/Bilbao, 1, 5º
03001 Alicante
ES
goods and services
5
Medical and pharmaceutical preparations, Both prescription and over-the-counter, For humans and animals, Specifically, for the treatment and prevention of diseases of the central nervous system, neurological diseases and Psychiatric diseases; Pharmaceutical preparations for the treatment and prevention of cerebral ischemia; Pharmaceutical preparations for the treatment and prevention of cerebral ischemia, Namely, Recovery after stroke, severe intracranial atherosclerosis, carotid artery endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; Pharmaceutical preparations for the treatment and prevention of cerebral and spinal cord injuries; Pharmaceutical preparations for the treatment and prevention of brain and spinal cord injuries, namely post-intracranial haemorrhage recovery, traumatic brain injury, spinal cord injury; Pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases; Pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases, Namely, Alzheimer's disease, Amotrophic lateral sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment caused by aging, progressive multiple sclerosis; Pharmaceutical preparations for the treatment and prevention of optic and retinal neuropathies; Pharmaceutical preparations for the treatment and prevention of optic and retinal neuropathies, namely glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathy; Pharmaceutical preparations for the treatment and prevention of pain; Pharmaceutical preparations for the treatment and Pain prevention, Namely, Opioid sparse analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the form of failed spinal surgery syndrome, radiculopathy in the form of sciatica, diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced neuropathy and drug-induced neuropathies, complex regional pain syndrome, fibromyalgia, Chronic pain following surgery, cluster thoracotomy, phantom pain, stump neuroma; Pharmaceutical preparations for the treatment and prevention of headaches and facial pain, Namely, Headache, migraine, daily chronic headache, cluster headache, trigeminal neuralgia; Pharmaceutical preparations for symptomatic treatments and prevention of degenerative diseases; Pharmaceutical preparations for symptomatic treatment and prevention of degenerative diseases, namely respiratory distress Rett syndrome, dystonia, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar influence, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; Pharmaceutical preparations for the treatment of epilepsy and Prevention of epileptic seizures; Pharmaceutical preparations for the treatment of epilepsy and Prevention of epileptic seizures, Namely, Precision drug adjuvant for genetic epilepsy caused by hyperactivation NMDA receptor mutations; Pharmaceutical preparations for the treatment and prevention of neuropsychiatric disorders; Pharmaceutical preparations for the treatment and prevention of neuropsychiatric disorders, Namely, Treatment-resistant depression, post-traumatic stress disorder (PTSD) in the form of hyperarousal, substance abuse disorders, addiction disorders, obsessive-compulsive disorder (OCD); Pharmaceutical preparations for the treatment and prevention of neuropsychiatric disorders, Namely, Hoarding disorder, trichotillomania, eating disorders, generalised anxiety disorder (GAD), adjustment disorders, panic disorders, depressive attacks, bipolar disorder in the form of manic and depressive attacks, dysthymia, cyclothymia, psychotic disorders, schizophrenia; Pharmaceutical preparations for the treatment and prevention of cerebellar disorders; Pharmaceutical preparations for the treatment and prevention of cerebellar disorders, Namely, Spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, significant tremor; Pharmaceutical preparations for the treatment and prevention of hearing problems, tinnitus, delirium, sleep disorders, parasomnia, learning difficulties, concentration disorders (ADD), pervasive developmental disorder (PDD), Asperger's syndrome, autism, hot flashes associated with menopause; Medicinal preparations for the treatment and prevention of cancer; Pharmaceutical preparations for the treatment and prevention of cancer, namely monotherapy and supplementary use
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| December 9, 2022 | Transfer / Change of address, Published | ||
| November 29, 2022 | RAW: Rights in rem - Cancellations of entries, Published | ||
| November 7, 2022 | Change Representative, Published | ||
| December 21, 2021 | RAW: Rights in rem - Creation of rights in rem, Published |
ID: 11018384392